Intra-patient dose escalation was not permitted in the dose-escalation cohorts. If a doselimiting toxicity (DLT) was observed in cycle 1 in a given cohort, dose escalation for subsequent cohorts was done by modified Fibonacci sequence, escalating by 50%, and then 33%, of the previous dose. DLTs were defined as any of the following events (per CTCAE version 3.0) occurring at any time during the study: any grade ≥3 toxicity (excluding suboptimally treated nausea, vomiting, and diarrhea); grade 3 hyperglycemia following a fast of 8 h; any grade 4 hyperglycemia; grade 4 neutropenia lasting ≥3 days; absolute neutrophil count <1000/mm 3 with fever ≥38ºC; and grade 4 thrombocytopenia. Dose escalation was stopped if two or more of six patients experienced a DLT in cycle 1.
portable glucometers, respectively. Safety evaluations included: physical examination; 12-lead electrocardiogram; echocardiography or multigated acquisition scan; vital signs; adverse events; and concomitant medications. Safety was assessed up to 30 days following the last dose of copanlisib.
Elevations in blood pressure were expected following copanlisib infusion based on preclinical data in laboratory animals, which observed dose-dependent peripheral vasoconstriction and elevation of blood pressure following intravenous administration of copanlisib (Bayer, data on file). Thus, blood pressure was monitored before, and at numerous intervals after, the start of infusion on day 1, at 0.5, 1, 1.5, 2, 3, 5, 8, 11, 25 , and 49 h. For subsequent cycles, blood pressure was monitored before and 1 h after the end of the infusion.
Hypertension was to be managed at the treating physician's discretion.
Serial plasma samples for single-dose and steady-state pharmacokinetic evaluation of copanlisib were collected on days 1 and 15, respectively, of cycle 1, at 0, 0.5, 1, 1.5, 2, 3, 5, 8, 11, 25 , and 49 h after the start of copanlisib infusion. A limited number of samples after multiple-dose administration was collected on cycle 3, day 15 from patients in the MTD expansion phase. Copanlisib plasma concentrations were determined after protein precipitation followed by separation employing liquid chromatography coupled with tandem mass spectrometry. The nominal calibration ranges for copanlisib were 0.5 µg/l (lower limit of quantitation) to 265 µg/l (upper limit of quantitation), and 2 µg/l (lower limit of quantitation) to 1057 µg/l (upper limit of quantitation).
For [
18 F]-fluorodeoxyglucose positron emission tomography ( 18 FDG-PET) scans, blood glucose was to be <160 mg/dl. 18 FDG-PET image evaluation was conducted centrally.
Population pharmacodynamic models were used to link pharmacodynamic data to plasma copanlisib concentrations.
response assessments
A central review of the efficacy assessment for patients with non-Hodgkin's lymphoma was performed retrospectively.
management and grading of hyperglycemia
Insulin administration at home was based on measurements of capillary blood glucose.
CTCAE version 3.0 severity grading was applied to post-prandial blood glucose values following copanlisib infusion.
biomarker assessments
All biomarker analyses were retrospective and exploratory except for the requirement to enroll at least eight patients harboring PIK3CA mutations in the solid-tumor expansion cohort. Tumor tissues (where available) and/or circulating tumor DNA from plasma collected at baseline were centrally assayed at screening for the presence of PIK3CA Fifty-two patients (91%), including all patients treated at the MTD (0.8 mg/kg), had increases in plasma insulin more than twice baseline levels following copanlisib infusion, although use of short-acting insulin in a majority of patients confounded the interpretation of these results.
response
In the diffuse large B-cell lymphoma patient with a partial response, objective response could not be confirmed because of treatment discontinuation at cycle 10 as a result of a perirectal abscess. The two patients with diffuse large B-cell lymphoma who had disease progression discontinued from the study at the end of cycles 1 and 2, respectively. (100) 3 (100) 7 (100) 3 (100) 25 (100) 9 (100) 6 (100) 57 (100) AEs of grade 3 or 4, regardless of causality Grade 3 1 (100) 3 (100) 3 (100) 5 (71) 2 (67) 17 (68) 7 (78) 3 (50) 41 (72) Grade 4 (11) 1 (17) 4 (7) a All AEs were defined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
b Two additional patients experienced a total of three grade 4 events, in addition to a grade 5 event each; therefore, the worst grade AE, regardless of causality, for these two patients was grade 5 and so they are not included here.
AE, adverse event; NHL, non-Hodgkin's lymphoma. HbA1c, %, mean ± SEM At baseline 5.4 ± 0.3 6.0 ± 0.2 7.4 ± 1.2
After treatment with copanlisib 5.9 ± 0.5 6.3 ± 0.7 7.3 ± 1.1 a Diabetic patients received short-acting insulin and oral glucose-lowering agents following copanlisib infusion.
HbA1c, hemoglobin A1c; SEM, standard error of the mean. BEAMing, beads, emulsions, amplification, and magnetics technology; CR, complete response; DLBCL, diffuse large B-cell lymphoma; ER/PR, estrogen receptor/progesterone receptor; HER2, human epidermal growth factor receptor 2; mut, mutation; N, mutational status was assessed using next-generation sequencing of DNA isolated from tumor tissue; NA, not available; NSCLC, non-small-cell lung cancer; P, mutational status was assessed from DNA isolated from plasma sample by BEAMing (Sysmex Inostics GmbH, Hamburg, Germany); PD, progressive disease; PR, partial response; PRc, confirmed partial response; PRu, unconfirmed partial response; SD, stable disease; T, mutational status was assessed from DNA isolated from tumor by BEAMing; TNBC, triple-negative breast cancer; WT, wild type. 
